https://mindmedicinelaw.com/briefing/addressing-lessebo-effects-in-psychedelic-trials-20260709-20662The Psychedelic Journalen2026-07-10T15:05:06.968232+00:00Addressing Lessebo Effects in Psychedelic Trialspsychedelic trials, lessebo effect, blinding integrity, psychoeducation, therapeutic alliance, expectancy bias, placebo effect, clinical validity, ethical rigor, trial outcomeshttps://mindmedicinelaw.com/briefing/real-world-outcomes-of-esketamine-and-ketamine-for-trd-20260709-20676The Psychedelic Journalen2026-07-10T15:04:45.742740+00:00Real-World Outcomes of Esketamine and Ketamine for TRDesketamine, ketamine, treatment-resistant depression, community clinic, real-world outcomes, NMDA receptor antagonists, clinical efficacy, insurance coverage, long-term effects, TRD treatmenthttps://mindmedicinelaw.com/briefing/ketamine-s-role-in-addiction-treatment-promise-and-perils-20260709-20628The Psychedelic Journalen2026-07-10T15:04:33.828021+00:00Ketamine's Role in Addiction Treatment: Promise and Perilsketamine, addiction treatment, substance use disorders, treatment-resistant depression, neuroplasticity, misuse liability, clinical trials, psychiatric treatmenthttps://mindmedicinelaw.com/briefing/new-guidelines-for-iv-ketamine-in-clinical-practice-20260709-20583The Psychedelic Journalen2026-07-09T22:03:51.690891+00:00New Guidelines for IV Ketamine in Clinical Practiceintravenous ketamine, clinical practice guidelines, mental health care, treatment protocols, patient safety, ketamine therapy, psychiatric disorders, treatment-resistant depression, NMDA receptor, psychedelic medicinehttps://mindmedicinelaw.com/briefing/psilocybin-s-potential-in-anorexia-treatment-trial-insights-20260709-20582The Psychedelic Journalen2026-07-09T22:03:37.307572+00:00Psilocybin's Potential in Anorexia Treatment: Trial Insightspsilocybin therapy, anorexia nervosa treatment, psychedelic research, clinical trials, mental health, FDA regulation, serotonin receptors, eating disorders, psychedelic-assisted therapyhttps://mindmedicinelaw.com/briefing/bridging-iv-ketamine-use-with-evidence-based-standards-20260709-20423The Psychedelic Journalen2026-07-09T15:05:11.697904+00:00Bridging IV Ketamine Use with Evidence-Based StandardsIV ketamine, evidence-based standards, psychiatric disorders, NMDA receptor, clinical trials, patient safety, treatment protocols, regulatory bodies, adverse effects, long-term outcomeshttps://mindmedicinelaw.com/briefing/serotonin-1b-receptor-increases-with-ketamine-and-ect-20260708-20680The Psychedelic Journalen2026-07-10T15:05:19.012689+00:00Serotonin 1B Receptor Increases with Ketamine and ECTserotonin 1B receptor, ketamine, electroconvulsive therapy, major depressive disorder, PET imaging, Bayesian analysis, depression treatmenthttps://mindmedicinelaw.com/briefing/dmt-trials-show-promise-for-anxiety-and-life-satisfaction-20260708-20665The Psychedelic Journalen2026-07-10T15:04:55.844471+00:00DMT Trials Show Promise for Anxiety and Life SatisfactionDMT trials, anxiety improvement, life satisfaction, treatment-resistant depression, psychedelic therapies, clinical trials, public health strategies, quality of life, mental health treatment, psychedelic researchhttps://mindmedicinelaw.com/briefing/fda-issues-ketamine-warning-amid-psychedelic-safety-concerns-20260708-20421The Psychedelic Journalen2026-07-09T15:05:25.276993+00:00FDA Issues Ketamine Warning Amid Psychedelic Safety ConcernsFDA ketamine warning, psychedelic safety concerns, clinical trials impact, regulatory scrutiny, public perception, psychedelic therapies, ketamine adverse effects, pharmaceutical distribution risks, legal implications, market dynamicshttps://mindmedicinelaw.com/briefing/psilocybin-therapy-pilot-for-anorexia-nervosa-promising-results-20260708-20311The Psychedelic Journalen2026-07-09T15:04:57.753187+00:00Psilocybin Therapy Pilot for Anorexia Nervosa: Promising Resultspsilocybin therapy, anorexia nervosa, clinical trials, eating disorders, psychedelic research, mental health treatment, COMP360, safety and efficacy, pilot study, treatment innovationhttps://mindmedicinelaw.com/briefing/esketamine-s-role-in-reducing-post-surgery-depression-in-breast-cancer-patients-20260708-20358The Psychedelic Journalen2026-07-09T15:04:45.864407+00:00Esketamine's Role in Reducing Post-Surgery Depression in Breast Cancer Patientsesketamine, postoperative depression, breast cancer surgery, perioperative care, randomized controlled trials, analgesic effects, depressive symptoms, clinical guidelines, evidence uncertainty, patient recoveryhttps://mindmedicinelaw.com/briefing/ketamine-use-surge-in-uk-raises-health-concerns-20260708-20106The Psychedelic Journalen2026-07-08T22:04:14.381200+00:00Ketamine Use Surge in UK Raises Health Concernsketamine use, public health, harm reduction, UK drug policy, ketamine bladder syndrome, NMDA receptors, drug misuse, therapeutic ketamine, pain management, regulatory approacheshttps://mindmedicinelaw.com/briefing/fda-targets-illegal-ketamine-sellers-amid-psychedelic-growth-20260708-20262The Psychedelic Journalen2026-07-08T22:04:03.748584+00:00FDA Targets Illegal Ketamine Sellers Amid Psychedelic GrowthFDA, ketamine, psychedelic regulation, illegal sales, mental health, compliance, clinical trials, market expansion, public health, therapeutic potentialhttps://mindmedicinelaw.com/briefing/texas-advances-ibogaine-research-without-pharma-partner-20260707-20741The Psychedelic Journalen2026-07-10T15:05:34.039940+00:00Texas Advances Ibogaine Research Without Pharma Partneribogaine research, Texas state-funded program, addiction treatment, psychedelic substances, pharmaceutical partnerships, drug policy, clinical trials, substance use disorders, psychoactive compounds, regulatory challengeshttps://mindmedicinelaw.com/briefing/endothelial-cb1-receptor-s-role-in-atherosclerosis-explored-20260707-20359The Psychedelic Journalen2026-07-09T22:04:20.508206+00:00Endothelial CB1 Receptor's Role in Atherosclerosis Exploredendothelial CB1 receptor, atherosclerosis, vascular inflammation, lipid uptake, sex-biased mechanism, drug development, metabolic diseases, estrogen signaling, cardiovascular healthhttps://mindmedicinelaw.com/briefing/ionic-homeostasis-in-mdd-implications-for-precision-therapies-20260707-20363The Psychedelic Journalen2026-07-09T22:04:12.087935+00:00Ionic Homeostasis in MDD: Implications for Precision Therapiesionic homeostasis, major depressive disorder, ion-channel systems, precision therapeutics, ketamine mechanisms, treatment-resistant depression, neuroinflammation, excitation-inhibition imbalancehttps://mindmedicinelaw.com/briefing/brain-based-depression-subtypes-new-study-insights-20260707-20313The Psychedelic Journalen2026-07-09T15:05:51.401049+00:00Brain-Based Depression Subtypes: New Study Insightsmajor depressive disorder, brain-based subtypes, neurotransmitter systems, cortical thickness, dopamine transporter, histamine receptor H3, personalized treatment, psychiatric research, neuroimaging, mental healthhttps://mindmedicinelaw.com/briefing/slc36a1-transporter-structure-implications-for-cns-drug-delivery-20260707-20361The Psychedelic Journalen2026-07-09T15:05:37.703784+00:00SLC36A1 Transporter Structure: Implications for CNS Drug DeliverySLC36A1 transporter, CNS drug delivery, cryo-EM structure, amino-acid transport, oral drug design, neuroscience research, proton-coupled transport, blood-brain barrier, pharmacokinetics, drug absorptionhttps://mindmedicinelaw.com/briefing/gut-microbiota-and-cognitive-impairment-in-mdd-new-insights-from-china-20260707-20042The Psychedelic Journalen2026-07-08T22:04:41.128967+00:00Gut Microbiota and Cognitive Impairment in MDD: New Insights from Chinagut microbiota, oxidative stress, cognitive impairment, major depressive disorder, mental health research, therapeutic strategies, China pilot study, inflammation, psychobiotics, brain-gut axishttps://mindmedicinelaw.com/briefing/2-adrenergic-receptor-s-impact-on-mdma-psilocybin-effects-20260707-20102The Psychedelic Journalen2026-07-08T22:04:31.948415+00:00α(2)-Adrenergic Receptor's Impact on MDMA, Psilocybin Effectsα(2)-adrenergic receptor, 5-HT(2A) receptor, MDMA effects, psilocybin effects, psychedelic therapy, receptor interactions, clinical trials, neuroscience, safety profiles, therapeutic strategieshttps://mindmedicinelaw.com/briefing/biopsychosocial-insights-into-stress-induced-psychopathology-20260707-20015The Psychedelic Journalen2026-07-08T22:04:22.039730+00:00Biopsychosocial Insights into Stress-Induced Psychopathologystress-induced psychopathology, biopsychosocial model, anxiety disorders, neurobiological factors, genetic influences, personalized interventions, PTSD symptom fluctuation, bioenergetic signatures, complex systems, psychiatric disordershttps://mindmedicinelaw.com/briefing/srp-and-empathy-in-mental-disorders-neural-insights-20260706-19837The Psychedelic Journalen2026-07-09T22:04:29.746097+00:00SRP and Empathy in Mental Disorders: Neural Insightsself-referential processing, empathy-based interventions, psychedelic-assisted psychotherapy, neural mechanisms, mental disorders, precision psychiatry, default mode network, medial prefrontal cortex, cognitive biases, biomarker identificationhttps://mindmedicinelaw.com/briefing/congressional-bill-proposes-psychedelics-study-for-military-20260706-20584The Psychedelic Journalen2026-07-09T22:04:01.993462+00:00Congressional Bill Proposes Psychedelics Study for Militarypsychedelic mushrooms, military mental health, congressional bill, psilocybin research, Department of Defense, mental health protocols, PTSD treatment, psychedelic therapy, federal policy, veteran mental healthhttps://mindmedicinelaw.com/briefing/biomarker-guided-antidepressant-trial-for-mdd-insights-implications-20260706-20044The Psychedelic Journalen2026-07-08T22:04:58.147974+00:00Biomarker-Guided Antidepressant Trial for MDD: Insights & Implicationsbiomarker-guided treatment, major depressive disorder, bupropion, sertraline, precision medicine, clinical trial, antidepressant response, personalized treatment, biobehavioral markers, mental health research